Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

10.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.7K
Chirality in Nature02:30

Chirality in Nature

14.6K
Chirality is the most intriguing yet essential facet of nature, governing life’s biochemical processes and precision. It can be observed from a snail shell pattern in a macroscopic world to an amino acid, the minutest building block of life. Most of the snails around the world have right-coiled shells because of the intrinsic chirality in their genes. All the amino acids present in the human body exist in an enantiomerically pure state, except for glycine - the sole achiral amino acid.
14.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

293
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
293

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BFLF1 gene polymorphisms are associated with increased mortality in patients with EBV-associated diseases.

Hereditas·2026
Same author

Scalable quasi-pure MOF membranes for energy-efficient gas separations.

Nature·2026
Same author

Peptide-Functionalized Hydroxypropyl Cellulose Mitigates Amyloid-β Protein Induced Endothelial Leakiness and Enhances Cognitive Function in Alzheimer's Disease.

Angewandte Chemie (International ed. in English)·2026
Same author

Quantitative DNA/RNA fragmentation assays for estimating the time since deposition (TsD) of bloodstains.

Forensic science international. Genetics·2026
Same author

Site-resolved exploration of high-entropy alloy hydrogen evolution reaction catalysts <i>via</i> interpretable modelling and high-throughput density functional theory.

Physical chemistry chemical physics : PCCP·2026
Same author

Caregiver guilt as an underrecognised burden in family cancer caregiving: a scoping review and implications for palliative care support.

BMC palliative care·2026

Related Experiment Video

Updated: Oct 14, 2025

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.1K

Artificial Chiral Interfaces against Amyloid-β Peptide Aggregation: Research Progress and Challenges.

Zhe Zhou1, You-Quan Gu1, Hang-Xing Wang2

  • 1Department of Neurology, The First Hospital of Lanzhou University, Lanzhou 730000, China.

ACS Chemical Neuroscience
|November 1, 2021
PubMed
Summary

Chiral nanostructures show promise in inhibiting amyloid-beta (Aβ) aggregation, a key factor in Alzheimer's disease (AD). Understanding the molecular mechanisms of these chiral inhibitors is crucial for developing new anti-amyloid drugs.

Keywords:
Aβ aggregation inhibitionD/L enantiomersNanostructureschiral interfaceenantioselectivity

More Related Videos

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.1K
Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
08:53

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Published on: March 21, 2025

918

Related Experiment Videos

Last Updated: Oct 14, 2025

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.1K
A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.1K
Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
08:53

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Published on: March 21, 2025

918

Area of Science:

  • Nanomedicine
  • Neurodegenerative Disorders
  • Biochemistry

Background:

  • Alzheimer's disease (AD) involves amyloid-beta (Aβ) aggregation, impacting patient quality of life and societal burden.
  • Engineered nanostructures are emerging as potential inhibitors of Aβ aggregation.
  • The role of chirality in nanostructure-based Aβ inhibition remains underexplored.

Purpose of the Study:

  • To review experimental and theoretical findings on artificial chiral nanostructures as Aβ amyloid inhibitors.
  • To elucidate the molecular mechanisms by which chiral nanointerfaces affect Aβ recognition and aggregation.
  • To highlight the potential of chiral nanostructures in developing novel anti-amyloidosis drugs.

Main Methods:

  • Review of recent experimental studies on chiral nanostructures and Aβ aggregation.
  • Analysis of theoretical models investigating chiral effects at the nano-bio interface.
  • Synthesis of current knowledge on nanostructure surface properties (morphology, charge, hydrophobicity) and their influence on Aβ adsorption.

Main Results:

  • Chirality has been largely overlooked in the design of Aβ aggregation inhibitors.
  • Nanostructural surface properties influence Aβ peptide adsorption and subsequent aggregation.
  • Emerging evidence suggests chiral nanostructures can modulate Aβ recognition and aggregation pathways.

Conclusions:

  • Chiral nanostructures represent a novel frontier in nanomedicine for targeting Alzheimer's disease.
  • Further research into the molecular mechanisms of chiral nano-Aβ interactions is essential.
  • Development of chiral inhibitor drugs holds significant therapeutic potential against Aβ fibrillation.